Successful treatment of MuSK antibody-positive myasthenia gravis with rituximab

Introduction: MuSK antibody (ab)-positive patients seem to be different from those with acetylcholine receptor (AChR) ab-positive myasthenia by predominant oculobulbar involvement. Some of them poorly respond to classical immunosuppression. Although plasma exchange causes an improvement in most of these cases, other new options of immunotherapy have to be considered. Rituximab has been administered successfully in patients with AChR ab-positive myasthenia gravis, but no patients with MuSK antibodies have been published until now. Methods: A 56-year-old patient presenting with predominantly bulbar symptoms (ptosi…